Epigral Limited — Investor Meet, 06-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Epigral reported strong Q4 FY26 results with highest ever revenue of INR 736 Cr (up 22% QoQ) and EBITDA of INR 169 Cr (up 64% QoQ), reflecting improved plant utilization over 80%. Full-year FY26 revenue was INR 2,542 Cr. Management expects 10-12% volume growth in FY27, driven by higher value products, making FY27 look "much better." Capacity expansions for ECH and CPVC are on track for Q2 FY27 commissioning. Chlorotoluene is ramping up, expecting significant contribution in FY27. A new greenfield project is under evaluation, with an announcement expected this year. The company remains resilient despite global uncertainties due to its diversified product portfolio.